Amgen: Leqembi finally secures EU clearance; Sandoz sues Amgen over Enbrel patents
After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz is alleging Amgen's patent actions were anticompetitive.
Read full article »
Amgen is a California-based multinational biopharmaceutical company that develops human therapeutics for the treatment of diseases including cancer and cardiovascular.
Read more